Literature DB >> 3311924

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.

K Bertelsen1, A Jakobsen, J E Andersen, S Ahrons, P H Pedersen, H Kiaer, E Arffmann, P Bichel, E Boestofte, I Strøyer.   

Abstract

Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3311924     DOI： 10.1016/0090-8258(87)90210-1

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

2.  Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.

Authors:  M Suzuki; S Saito; Y Saga; M Ohwada; I Sato
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

3.  Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).

Authors:  S Marsoni; V Torri; M G Valsecchi; C Belloni; U Bianchi; G Bolis; C Bonazzi; N Colombo; A Epis; G Favalli
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

4.  A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.

Authors:  V J O'Neill; S B Kaye; N S Reed; J Paul; J A Davis; P A Vasey
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

Review 5.  Docetaxel: promising and novel combinations in ovarian cancer.

Authors:  J U Mäenpää
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

6.  Protocol allocation and exclusion in two Danish randomised trials in ovarian cancer.

Authors:  K Bertelsen
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

7.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

8.  Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).

Authors:  Arlindo R Ferreira; Otto Metzger-Filho; Roberta M B Sarmento; José Bines
Journal:  Front Oncol       Date:  2018-01-24       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.